Peter Llewellyn-Davies

1 POSTS 0 COMMENTS
Peter is Chief Executive Officer of APEIRON Biologics, a biotech company focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON are currently investigating a therapeutic candidate for the treatment of severe COVID-19.Latest articles
COVAX delivers 600,000 vaccines to Ghana in bid for global equality
COVAX has shipped 600,000 doses of the Oxford/AstraZeneca vaccine, from the Serum Institute of India (SII) to Ghana. The arrival in Accra, the capital...
NHS prescription charge to increase from 1 April 2021
The NHS prescription charge will increase to £9.35 per prescription item from 1 April 2021 in England, according to the Pharmaceutical Services Negotiating Committee...
Sanofi and GSK start new study of COVID-19 vaccine
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study with 720 volunteers aged 18 and over to select the...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nasal spray to protect against COVID-19 is ready for use in humans
A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
JCVI updates priority list for COVID-19 vaccine
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that the first priorities for any COVID-19 vaccination programme should be the prevention of...
NHS prescription charge to increase from 1 April 2021
The NHS prescription charge will increase to £9.35 per prescription item from 1 April 2021 in England, according to the Pharmaceutical Services Negotiating Committee...